KR20220066914A - 부정맥 유발성 우심실 심근병증의 유전자 요법 조성물 및 치료 - Google Patents

부정맥 유발성 우심실 심근병증의 유전자 요법 조성물 및 치료 Download PDF

Info

Publication number
KR20220066914A
KR20220066914A KR1020227012607A KR20227012607A KR20220066914A KR 20220066914 A KR20220066914 A KR 20220066914A KR 1020227012607 A KR1020227012607 A KR 1020227012607A KR 20227012607 A KR20227012607 A KR 20227012607A KR 20220066914 A KR20220066914 A KR 20220066914A
Authority
KR
South Korea
Prior art keywords
pkp2
leu
gene therapy
ser
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227012607A
Other languages
English (en)
Korean (ko)
Inventor
토머스 보이트
줄리 두몬소
페리 엘리엇
버진 마리오트
Original Assignee
유씨엘 비즈니스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유씨엘 비즈니스 리미티드 filed Critical 유씨엘 비즈니스 리미티드
Publication of KR20220066914A publication Critical patent/KR20220066914A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4716—Muscle proteins, e.g. myosin, actin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14145—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020227012607A 2019-09-20 2020-09-21 부정맥 유발성 우심실 심근병증의 유전자 요법 조성물 및 치료 Pending KR20220066914A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962903103P 2019-09-20 2019-09-20
US62/903,103 2019-09-20
PCT/EP2020/076290 WO2021053222A1 (en) 2019-09-20 2020-09-21 Gene therapy composition and treatment of right ventricular arrythmogenic cardiomyopathy

Publications (1)

Publication Number Publication Date
KR20220066914A true KR20220066914A (ko) 2022-05-24

Family

ID=72615856

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227012607A Pending KR20220066914A (ko) 2019-09-20 2020-09-21 부정맥 유발성 우심실 심근병증의 유전자 요법 조성물 및 치료

Country Status (9)

Country Link
US (3) US20220389452A1 (cg-RX-API-DMAC7.html)
EP (1) EP4031672A1 (cg-RX-API-DMAC7.html)
JP (2) JP2022549140A (cg-RX-API-DMAC7.html)
KR (1) KR20220066914A (cg-RX-API-DMAC7.html)
AU (1) AU2020350140A1 (cg-RX-API-DMAC7.html)
CA (1) CA3151036A1 (cg-RX-API-DMAC7.html)
IL (1) IL291488A (cg-RX-API-DMAC7.html)
TW (1) TWI897882B (cg-RX-API-DMAC7.html)
WO (1) WO2021053222A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114450411A (zh) 2019-04-01 2022-05-06 特纳亚治疗股份有限公司 具有工程化衣壳的腺相关病毒
WO2021142267A1 (en) * 2020-01-08 2021-07-15 Scarpmap Llc Methods and computing system for processing ultrasound image to determine health of subdermal tissue
FI4103214T3 (fi) 2020-02-13 2026-07-03 Tenaya Therapeutics Inc Geeniterapian vektorit sydänsairauden hoitoon
WO2022032226A1 (en) * 2020-08-07 2022-02-10 Spacecraft Seven, Llc Plakophilin-2 (pkp2) gene therapy using aav vector
JP7415042B2 (ja) 2020-10-09 2024-01-16 テナヤ セラピューティクス, インコーポレイテッド プラコフィリン2遺伝子治療の方法および組成物
US11781156B2 (en) * 2020-10-09 2023-10-10 Tenaya Therapeutics, Inc. Plakophillin-2 gene therapy methods and compositions
CA3212043A1 (en) * 2021-03-19 2022-09-22 Ucl Business Plc Gene therapy composition and treatment of right ventricular arrhythmogenic cardiomyopathy
BR112023021037A2 (pt) * 2021-04-12 2023-12-19 Univ California Terapia gênica para cardiomiopatia ventricular direita arritmogênica
WO2023159190A1 (en) * 2022-02-18 2023-08-24 Ginkgo Bioworks, Inc. Gene therapy for arrhythmogenic cardiomyopathy
IL315695A (en) * 2022-03-18 2024-11-01 Univ Florida Methods and compositions for treating RBM20-associated cardiomyopathy with a viral vector
EP4507713A4 (en) * 2022-04-11 2026-04-15 Tenaya Therapeutics Inc PLAKOPHILIN-2 BASED GENE THERAPY TREATMENT METHODS
US20260102513A1 (en) * 2022-09-21 2026-04-16 Rejuvenate Bio Gene therapy methods for arrhythmogenic cardiomyopathy
UY40442A (es) * 2022-09-22 2024-02-15 Biomarin Pharm Inc Tratamiento de la miocardiopatía arritmogénica con vectores de genoterapia con aav
CN116064612A (zh) * 2022-11-17 2023-05-05 百世诺(北京)医疗科技有限公司 肥厚型心肌病变异基因alpk3及其应用
CN122161621A (zh) * 2023-07-06 2026-06-05 加利福尼亚大学董事会 Alpk3心肌病的基因替代疗法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2792742A1 (en) * 2013-04-17 2014-10-22 Universitätsklinikum Hamburg-Eppendorf (UKE) Gene-therapy vectors for treating cardiomyopathy
WO2017083750A1 (en) * 2015-11-11 2017-05-18 Intrexon Corporation Compositions and methods for expression of multiple biologically active polypeptides from a single vector for treatment of cardiac conditions and other pathologies
WO2018208998A1 (en) * 2017-05-10 2018-11-15 The Regents Of The University Of California Directed editing of cellular rna via nuclear delivery of crispr/cas9
WO2019060619A1 (en) * 2017-09-20 2019-03-28 The Regents Of The University Of California STRATEGY OF GENE THERAPY FOR RESTORING ELECTRICAL AND CARDIAC FUNCTION AND CARDIAC STRUCTURE IN ARYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY
DK3684423T5 (da) * 2017-09-20 2024-08-26 4D Molecular Therapeutics Inc Adeno-associerede virusvariantcapsider og fremgangsmåder til anvendelse deraf
CA3097375A1 (en) * 2018-04-27 2019-10-31 Universitat Heidelberg Modified aav capsid polypeptides for treatment of muscular diseases
CN109004092A (zh) 2018-06-29 2018-12-14 云谷(固安)科技有限公司 有机电致发光器件和有机电致发光装置
WO2022032226A1 (en) * 2020-08-07 2022-02-10 Spacecraft Seven, Llc Plakophilin-2 (pkp2) gene therapy using aav vector

Also Published As

Publication number Publication date
JP2022549140A (ja) 2022-11-24
US20220389452A1 (en) 2022-12-08
IL291488A (en) 2022-05-01
TWI897882B (zh) 2025-09-21
US20240076696A1 (en) 2024-03-07
WO2021053222A1 (en) 2021-03-25
JP2026116276A (ja) 2026-07-09
US20250163470A1 (en) 2025-05-22
TW202126674A (zh) 2021-07-16
EP4031672A1 (en) 2022-07-27
CA3151036A1 (en) 2021-03-25
AU2020350140A1 (en) 2022-03-31

Similar Documents

Publication Publication Date Title
AU2020201190B2 (en) Compositions useful in treatment of ornithine transcarbamylase (OTC) deficiency
KR20230159471A (ko) 우심실 부정맥성 심근병증의 유전자 치료 조성물 및 치료
CN112522271B (zh) 一种sgRNA及其应用
AU2018265258B2 (en) Enveloped virus resistant to complement inactivation for the treatment of cancer
KR102673828B1 (ko) off-the-shelf 줄기세포 및 면역세포, 이를 포함하는 약학적 조성물
JP2022549140A (ja) 遺伝子療法組成物および不整脈源性右心室心筋症の治療
KR101258949B1 (ko) 활성형 재조합 혈액응고 9인자의 대량생산 방법
CN110177577A (zh) Sfasl的aav2介导的基因递送作为青光眼的神经保护疗法
CN112877351A (zh) 一种用于防治新冠病毒感染的重组质粒、重组乳酸杆菌表达系统及其应用
WO2024123200A1 (en) A nucleic acid construct for use in the gene therapy for glaucoma
KR101885438B1 (ko) 유전자치료 벡터시스템 및 전구약물 유전자
CN112342228B (zh) 表达抗vegf融合蛋白的aav病毒载体及其应用
AU2021254852B2 (en) Gene therapy for Bardet-Biedl syndrome
CN111793632A (zh) 变异的Gsdmd-C核酸片段,包含所述核酸片段的载体及应用
TWI902721B (zh) 前庭支持細胞啟動子及其用途
CN112301058B (zh) 一种重组腺相关病毒载体及其制备方法与应用
CN110225977B (zh) 基因治疗载体系统和药物前体基因
US6548301B2 (en) Retroviral gene transfer vectors
CN112301057B (zh) 一种重组腺相关病毒载体及其制备方法与应用
CN109735558B (zh) 一种重组car19-il24基因、慢病毒载体、car19-il24-t细胞及应用
CN114686521A (zh) 一种重组腺相关病毒载体及其制备方法与应用
WO2025062355A1 (en) Stem cell lines containing endogenous marked proteins with differential expression, production methods and their use for cell cycle identification
KR20230152503A (ko) 척수강 내 투여에 최적화 된 간세포 성장인자 유전자가 도입된 aav 벡터
RU2791051C2 (ru) Оболочечный вирус, резистентный к инактивации комплементом, для лечения злокачественных новообразований
KR20110135724A (ko) 사람의 sod-3 유전자를 가지는 형질전환 닭

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000